T-cell prolymphocytic leukemia with active disease: what to do when alemtuzumab induction therapy has not achieved complete remission

This protocol addresses T-cell prolymphocytic leukemia (T-PLL) patients with documented active disease who did not reach the targeted response — complete remission — following first-line IV alemtuzumab induction and consolidation. At this juncture, a structured next-line approach is required.

Active disease — criteria defining the need for treatment

Treatment is indicated when T-PLL meets at least one of the following criteria:

Significant fatigue (ECOG ≥ 2)
Unintentional weight loss > 10% of body weight within ≤ 6 months
Drenching night sweats without evidence of infection
Fever > 38°C without evidence of infection
Hemoglobin < 10 g/dL
Platelet count < 100 × 10&sup9;/L
Rapidly enlarging lymph nodes, spleen, or liver
Increasing lymphocytosis
Extranodal involvement

First-line failure — what was targeted and why escalation is needed

First-line therapy consists of IV alemtuzumab induction over 10 to 12 weeks, followed by consolidation with allogeneic stem cell transplant — or autologous transplant where no suitable donor is available. The goal is best response, ideally complete remission: absence of lymphadenopathy, splenomegaly, and hepatomegaly; circulating lymphocyte count below 4 × 10&sup9;/L; and T-PLL cells below 5% of mononuclear cells in bone marrow. This protocol is for patients who did not meet those response criteria.

Next-line approach — partial overview

After failure of alemtuzumab-based induction, treatment moves to salvage chemotherapy and/or immunotherapy regimens. The specific choice among available options depends on individual clinical factors — the full structured protocol details the regimens, selection criteria, and sequencing. At relapse, outcomes are challenging, making a rigorous evidence-based framework at this decision point especially important.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood.2019000402

Treatment is indicated for patients with active T-PLL and any of the listed disease-related symptoms (Table 4).

After relapse, the prognosis of T-PLL is dismal.

Salvage regimens (Table 6) can achieve an ORR 50% to 76%, but only short duration and an OS of 6 to 9 months.

View source ↗